Targeting GLB1 in mice by CRISPR/Cas9 genome editing: Establishing a novel model for type II GM1 gangliosidosis
Elena‐Raluca Nicoli(National Institutes of Health), Cynthia J. Tifft(Children's National), Michal Tyrlík(National Institutes of Health), Yvonne L. Latour(National Institute of Neurological Disorders and Stroke), Jeeva Munasinghe Jeeva(National Institutes of Health), Danielle Donahue(National Institutes of Health), Richard L. Proia(National Institute of Diabetes and Digestive and Kidney Diseases), Robin Yoon(National Institutes of Health), Rohini Sidhu(Washington University in St. Louis), Mylene Huebecker(University of Oxford), Danielle Springer, Frances M. Platt(University of Oxford), Morteza Peiravi(National Institutes of Health), Andrea D'Souza(National Institutes of Health), Pamela Kell(Washington University in St. Louis), Maria T. Acosta, Xuntian Jiang(Washington University in St. Louis), Brianna Glase(National Institutes of Health)
Cited by 0
Related Papers
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium
|Nature Medicine|2008|833
Enhanced insulin sensitivity in mice lacking ganglioside GM3
|Proceedings of the National Academy of Sciences|2003|524
Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720
|Journal of Biological Chemistry|2004|444
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus–induced myeloid-derived suppressor cells in mice and humans
|Journal of Clinical Investigation|2008|349
The receptor S1P1 overrides regulatory T cell–mediated immune suppression through Akt-mTOR
|Nature Immunology|2009|331